Boston VA Healthcare System, Brockton
Brockton, Massachusetts, 02301, United States
Location status: Recruiting
NCT Number: NCT05299749
Neurofeedback intervention aimed to regulate the superior temporal gyrus (STG) activation and default mode network (DMN) connectivity as well as to reduce the auditory hallucinations (AH) schizophrenia patients with medication resistant AH.
Interested in participating?
Request Info18 year–55 year
All sexes
Interventional
Not applicable
Brockton, Massachusetts, 02301, United States
Location status: Recruiting
Here, the investigators propose that neurofeedback aimed to regulate the superior temporal gyrus (STG) activation will not only lead to activation changes in the STG, but also to changes in the default mode network (DMN), as well as to reductions in AH, and that the brain and clinical changes will be correlated. The theoretical framework for the current proposal is an AH model that assumes that AH result from abnormalities in a network of regions including STG, and medial prefrontal cortex (MPFC) and posterior cingulate cortex (PCC), the two latter regions are core medial hubs of DMN that are related to self-referential processing. This model is supported by several theoretical papers and experimental evidence well as preliminary data by the investigators (PD). In both R61 and R33 the investigators will study SZ patients with medication resistant AH in the rt-fMRI intervention arm and in the sham-rt-fMRI arm. In both arms, the task and the rt-fMRI session structure will be identical. The SZ-intervention group will receive feedback from the STG while SZ-sham group will receive feedback from the motor cortex. In addition, 2 functional fMRI tasks will examine the effect of rt-fMRI neurofeedback and of sham-rt-fMRI on brain response. This R33 phase will consist of an SZ-intervention group (random n=52) that will receive 5 sessions of rt-fMRI feedback targeting STG, while SZ-sham group (random n=52) will receive 5 sham-rt-fMRI sessions. Based on our R61 phase data, the investigators predict that rt-fMRI feedback aimed at STG will reduce AH which will be, in turn, associated with reductions in the STG activation and in the DMN connectivity (i.e., brain changes achieved in R61 and replicated in R33) in SZ- intervention group only. Five sessions of rt-fMRI feedback will address the question of dose response at brain and clinical levels. The impact of rt-fMRI neurofeedback and of sham-rt-fMRI on AH (primary outcome), and on delusions, negative symptoms and working memory (WM) (exploratory outcome) will be assessed with clinical and neuropsychological measures. In an exploratory aim, based on the existing literature, the investigators predict the improvement in delusions, negative symptoms and in WM score, only post-rt-fMRI neurofeedback targeting the STG and not post-sham-rt-fMRI.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
the patients will receive real-time feedback from the brain activity of the superior temporal gyrus
the patients will receive real-time feedback from the brain activity of the somato-motor cortex
Time frame: 0-4 weeks post intervention
does real-time fMRI neurofidback reduce BOLD activity in STG, post NFB
Time frame: 0-4 weeks post intervention
does real-time fMRI neurofidback reduce auditory hallucinations, post NFB
Time frame: 0-4 weeks post intervention
Does real time NFB reduce connectivity in MPFC-PCC, post NFB
Contact information is provided by the study sponsor or research team.
Clemens Bauer, phd
CONTACT
margaret niznikiewicz, PhD
CONTACT
Boston VA Research Institute, Inc.
Other
Real-time fMRI Neurofeedback as a Tool to Mitigate Auditory Hallucinations in Patients With Schizophrenia - R33 Phase
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05074732
Body Weight, Cardiovascular Diseases
Dublin, Ireland
View Trial DetailsNCT03076346
Mental Disorders, Psychotic Disorders
Pittsburgh, Pennsylvania, United States
View Trial DetailsNCT01431326
Adenoviridae Infections, Adenovirus
Anchorage, Alaska, United States
View Trial DetailsNCT03485131
Auditory Hallucination, Hallucinations
New York, United States
View Trial Details